Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | NATALEE: ribociclib and NSAI in HR+/HER2- early breast cancer

Kevin Kalinsky • 14 Sep 2024
ESMO 2024
Breast Cancer Ribociclib
monarchE NATALEE

Kevin Kalinsky, MD, MS, Emory University Hospital, Atlanta, GA, discusses findings from the NATALEE trial (NCT03701334) of ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) compared to NSAI alone in younger patients with HR+/HER2- early breast cancer (EBC). This analysis compares efficacy and safety in patients under 40 versus those 40 and older, and addition of ribociclib benefits in both age groups. The findings are additionally similar to the results of the monarchE (NCT03155997) trial. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Kalinsky

ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
Genomic assays and chemotherapy decisions in node-positive breast cancer
1:35
Genomic assays and chemotherapy decisions in node-positive breast cancer
Kevin Kalinsky • 31 May 2026
Ask the Expert: Kevin Kalinsky answers your breast cancer questions at ESMO 2025
9:15
Ask the Expert: Kevin Kalinsky answers your breast cancer questions at ESMO 2025
Kevin Kalinsky • 20 Oct 2025

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals